Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy

Personalized medicine in treating pancreatic ductal adenocarcinoma (PDAC) is still in its infancy, albeit PDAC-related deaths are projected to rise over the next decade. Only recently, maintenance therapy with the PARP inhibitor olaparib showed improved progression-free survival in germline BRCA1/2-...

Descripción completa

Detalles Bibliográficos
Autores principales: Roger, Elodie, Gout, Johann, Arnold, Frank, Beutel, Alica K., Müller, Martin, Abaei, Alireza, Barth, Thomas F. E., Rasche, Volker, Seufferlein, Thomas, Perkhofer, Lukas, Kleger, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563330/
https://www.ncbi.nlm.nih.gov/pubmed/32948057
http://dx.doi.org/10.3390/cells9092110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563330/
https://www.ncbi.nlm.nih.gov/pubmed/32948057
http://dx.doi.org/10.3390/cells9092110

Ejemplares similares